{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:46Z","timestamp":1792801666670,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15135-3","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:11:59Z","timestamp":1762341119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of cytogenetic abnormalities in Lebanese multiple myeloma patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Guitta","family":"Najem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Kharsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"El Karak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Wakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"El Ferkh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Farra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5582-2923","authenticated-orcid":false,"given":"Alain","family":"Chebly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"15135_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cca.2019.12.026","volume":"503","author":"N Gupta","year":"2020","unstructured":"Gupta N, Sharma A, Sharma A. Emerging biomarkers in multiple myeloma: a review. Clin Chim Acta. 2020;503:45\u201353.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"15135_CR2","first-page":"422","volume":"64","author":"G Bianchi","year":"2014","unstructured":"Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422\u201344.","journal-title":"CA Cancer J Clin"},{"key":"15135_CR3","doi-asserted-by":"crossref","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101(2):237\u2013244.","DOI":"10.1111\/ejh.13083"},{"issue":"1","key":"15135_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.46989\/001c.92555","volume":"6","author":"M Mattar","year":"2024","unstructured":"Mattar M, Bazarbachi A, Abduljalil O, Francis B, Alam A, Blunk V. Epidemiology. Treatment trends, and outcomes of multiple myeloma in the Middle East and Africa: a systematic review. Clin Hematol Int. 2024;6(1):67\u201383.","journal-title":"Clin Hematol Int"},{"issue":"6","key":"15135_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676\u201381.","journal-title":"Semin Oncol"},{"key":"15135_CR6","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 . Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534764\/. Cited 8 Sep 2024."},{"issue":"5","key":"15135_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jama.2021.25306","volume":"327","author":"J Silberstein","year":"2022","unstructured":"Silberstein J, Tuchman S, Grant SJ. What is multiple myeloma? JAMA. 2022;327(5):497.","journal-title":"JAMA"},{"key":"15135_CR8","unstructured":"Management of Newly Diagnosed Symptomatic Multiple Myeloma. Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 - ClinicalKey. Available from: https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S0025619613000773?scrollTo=%23hl0000728.\u00a0Cited 8 Sep 2024."},{"issue":"4","key":"15135_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.clml.2018.02.011","volume":"18","author":"C Cosemans","year":"2018","unstructured":"Cosemans C, Oben B, Arijs I, Dani\u00ebls A, Declercq J, Vanhees K, et al. Prognostic biomarkers in the progression from MGUS to multiple myeloma: a systematic review. Clin Lymphoma Myeloma Leuk. 2018;18(4):235\u201348.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10272","key":"15135_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"12","key":"15135_CR11","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u2013548.","journal-title":"Lancet Oncol"},{"issue":"6","key":"15135_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","volume":"17","author":"NC Munshi","year":"2011","unstructured":"Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res. 2011;17(6):1234\u201342.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"15135_CR13","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1080\/10428194.2020.1772475","volume":"61","author":"GR Mohyuddin","year":"2020","unstructured":"Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, et al. Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. Leuk Lymphoma. 2020;61(10):2519\u201322.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"15135_CR14","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","volume":"6","author":"S Giri","year":"2020","unstructured":"Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol. 2020;6(11):1759\u201365.","journal-title":"JAMA Oncol"},{"issue":"45","key":"15135_CR15","doi-asserted-by":"publisher","first-page":"78259","DOI":"10.18632\/oncotarget.20875","volume":"8","author":"JR Sawyer","year":"2017","unstructured":"Sawyer JR, Morgan GJ. Hyperhaploid karyotypes in multiple myeloma. Oncotarget. 2017;8(45):78259\u201360.","journal-title":"Oncotarget"},{"issue":"1","key":"15135_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00610-y","volume":"12","author":"M Martello","year":"2022","unstructured":"Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, et al. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. Blood Cancer J. 2022;12(1):15.","journal-title":"Blood Cancer J"},{"issue":"4","key":"15135_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s44228-022-00017-3","volume":"4","author":"A Ibrahim","year":"2022","unstructured":"Ibrahim A, Chamseddine N, El-Cheikh J, Hanna C, Moukadem W, Nasr F, et al. Management of multiple myeloma in the Middle East: unmet needs, challenges and perspective. Clin Hematol Int. 2022;4(4):127\u201332.","journal-title":"Clin Hematol Int"},{"issue":"1","key":"15135_CR18","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3.","journal-title":"Med Sci"},{"issue":"9","key":"15135_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1363","volume":"8","author":"H Hamdaoui","year":"2020","unstructured":"Hamdaoui H, Benlarroubia O, Ait Boujmia OK, Mossafa H, Ouldim K, Belkhayat A, et al. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Mol Genet Genomic Med. 2020;8(9):e1363.","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"15135_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the global burden of disease study 2016. J Hematol Oncol. 2019;12(1):136.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"15135_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bjhh.2016.01.005","volume":"38","author":"RK Kishimoto","year":"2016","unstructured":"Kishimoto RK, de Freitas SLVV, Ratis CA, Borri D, Sitnik R, Velloso EDRP. Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. Rev Bras Hematol Hemoter. 2016;38(2):113\u201320.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"15135_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1480793","volume":"14","author":"S Rammal","year":"2024","unstructured":"Rammal S, Abou Abdallah F, Attieh C, El Mounajjed Z, Semaan W, Chebly A. Complex karyotypes in hematologic disorders: a 12-year single-center study from Lebanon. Front Oncol. 2024;14:1480793.","journal-title":"Front Oncol"},{"issue":"3","key":"15135_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14740\/jh1007","volume":"11","author":"M Crabtree","year":"2022","unstructured":"Crabtree M, Cai J, Qing X. Conventional karyotyping and fluorescence in situ hybridization for detection of chromosomal abnormalities in multiple myeloma. J Hematol. 2022;11(3):87\u201391.","journal-title":"J Hematol"},{"issue":"1","key":"15135_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01286-w","volume":"15","author":"X Lu","year":"2025","unstructured":"Lu X, Andersen EF, Banerjee R, Eno CC, Gonzales PR, Kumar S, et al. Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the cancer genomics consortium plasma cell neoplasm working group. Blood Cancer J. 2025;15(1):86.","journal-title":"Blood Cancer J"},{"issue":"5","key":"15135_CR25","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20155034","volume":"49","author":"P Segges","year":"2016","unstructured":"Segges P, Braggio E, Minnicelli C, Hassan R, Zalcberg IR, Maiolino A. Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context. Braz J Med Biol Res. 2016;49(5):e5034.","journal-title":"Braz J Med Biol Res"},{"issue":"8","key":"15135_CR26","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Guti\u00e9rrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272\u20137.","journal-title":"Haematologica"},{"key":"15135_CR27","unstructured":"Chromosomal defects in multiple. myeloma - ClinicalKey. Available from: https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S0268960X24000018?scrollTo=%23hl0000595. Cited 8 Sep 2024."},{"issue":"1","key":"15135_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5644\/ama2006-124.242","volume":"48","author":"O Castaneda","year":"2019","unstructured":"Castaneda O, Baz R. Multiple myeloma genomics - a concise review. Acta Med Acad. 2019;48(1):57\u201367.","journal-title":"Acta Med Acad"},{"issue":"12","key":"15135_CR29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1159\/000520312","volume":"44","author":"M Heider","year":"2021","unstructured":"Heider M, Nickel K, H\u00f6gner M, Bassermann F. Multiple myeloma: molecular pathogenesis and disease evolution. Oncol Res Treat. 2021;44(12):672\u201381.","journal-title":"Oncol Res Treat"},{"issue":"20","key":"15135_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205169","volume":"14","author":"JM Rosa-Rosa","year":"2022","unstructured":"Rosa-Rosa JM, Cuenca I, Medina A, V\u00e1zquez I, S\u00e1nchez-delaCruz A, Buenache N, et al. NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial. Cancers. 2022;14(20):5169.","journal-title":"Cancers"},{"issue":"19","key":"15135_CR31","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1158\/1078-0432.CCR-21-0005","volume":"27","author":"N Sharma","year":"2021","unstructured":"Sharma N, Smadbeck JB, Abdallah N, Zepeda-Mendoza C, Binder M, Pearce KE, et al. The prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma. Clin Cancer Res. 2021;27(19):5430\u20139.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15135-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:12:01Z","timestamp":1762341121000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15135-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15135"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15135-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical committee at Saint Joseph University of Beirut and Hotel Dieu de France Hospital in Lebanon (CEHDF-1926). It was conducted in accordance with the ethical standards established by the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1715"}}